SCHEMBL4173385

SCHEMBL4173385

COc1ccc(Nc2nnc(-c3cccnc3C(N)c3cccnc3)[nH]2)c(OC)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
CYP1A2 P05177 2/20 0.39
CYP3A4 P08684 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
GAA P10253 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
POLB P06746 1/20 0.39
TSHR P16473 1/20 0.39
MAPT P10636 5/20 0.38
USP2 O75604 1/20 0.38
LMNA P02545 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
CCNA2 P20248 1/20 0.37
CDK2 P24941 1/20 0.37
TTK P33981 1/20 0.37
FLT3 P36888 1/20 0.36
MKNK1 Q9BUB5 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4181134 0.93 KDM4E (0.44) ALDH1A1NPC1CYP1A2CYP3A4CYP2C9
SCHEMBL4178005 0.86 MAPT (0.39) RAB9APOLBMAPTKDM4E
SCHEMBL4186196 0.86 TUBB4A (0.42) NPC1RAB9ASMN1; SMN2TSHRMAPT
SCHEMBL4172618 0.79 KCNA5 (0.48) ALDH1A1NPC1RAB9ACYP1A2CYP3A4
SCHEMBL4180853 0.78 KCNA5 (0.40) ALDH1A1CYP1A2CYP3A4CYP2C19NPSR1
SCHEMBL4173392 0.77 ALDH1A1 (0.49) ALDH1A1NPC1RAB9ACYP1A2CYP3A4
SCHEMBL4175489 0.77 NPY5R (0.47) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL4170892 0.76 TUBB4A (0.42) ALDH1A1MAPT
SCHEMBL4171271 0.75 TUBB4A (0.52) ALDH1A1NPC1RAB9ACYP1A2CYP3A4
SCHEMBL4181712 0.73 FYN (0.42) ALDH1A1NPC1RAB9AGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090318438-A1 Heterocyclic compounds and their use as anticancer agents CHEN XIAOLING 2009-12-24 US disclosed
US-20090048301-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS IMCLONE SYSTEMS INCORPORATED (US) 2009-02-19 US disclosed
WO-2005004818-A2 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS IMCLONE SYSTEMS INCORPORATED (US) 2005-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048301-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS TP53, MCL1, VHL ALDH1A1 535/4885NPC1 465/4885RAB9A 1835/4885
US-20090318438-A1 Heterocyclic compounds and their use as anticancer agents TP53, MCL1, VHL ALDH1A1 535/4885NPC1 465/4885RAB9A 1835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.